Compare TNDM & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNDM | BBNX |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 997.9M |
| IPO Year | 2013 | 2025 |
| Metric | TNDM | BBNX |
|---|---|---|
| Price | $16.46 | $18.59 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 24 | 13 |
| Target Price | ★ $28.55 | $23.28 |
| AVG Volume (30 Days) | ★ 2.1M | 1.4M |
| Earning Date | 11-05-2026 | 10-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 78.95 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,014,736,000.00 | $100,251,000.00 |
| Revenue This Year | $5.69 | $25.74 |
| Revenue Next Year | $12.35 | $44.51 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 7.93 | ★ 53.94 |
| 52 Week Low | $12.26 | $8.80 |
| 52 Week High | $29.65 | $32.71 |
| Indicator | TNDM | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 40.97 | 43.94 |
| Support Level | $14.54 | $15.76 |
| Resistance Level | $18.13 | $20.48 |
| Average True Range (ATR) | 1.04 | 1.37 |
| MACD | 0.07 | -0.40 |
| Stochastic Oscillator | 54.69 | 4.06 |
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on the Sigi tubeless patch pump. Tandem is also developing a fully closed-loop algorithm for its pumps. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 3 to 7 days.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.